ThinkEquity Upgrades Radiopharm Theranostics Limited – American Depositary Shares (NASDAQ:RADX) to “Strong-Buy”

Posted by on May 15th, 2025

Radiopharm Theranostics Limited – American Depositary Shares (NASDAQ:RADX – Get Free Report) was upgraded by analysts at ThinkEquity to a “strong-buy” rating in a report released on Monday,Zacks.com reports.

Separately, Maxim Group assumed coverage on shares of Radiopharm Theranostics Limited – American Depositary Shares in a research report on Thursday, May 1st. They issued a “buy” rating and a $12.00 price objective on the stock.

Check Out Our Latest Analysis on Radiopharm Theranostics Limited – American Depositary Shares

Radiopharm Theranostics Limited – American Depositary Shares Trading Up 11.1%

Shares of NASDAQ:RADX opened at $4.40 on Monday. Radiopharm Theranostics Limited – American Depositary Shares has a fifty-two week low of $3.50 and a fifty-two week high of $50.82.

About Radiopharm Theranostics Limited – American Depositary Shares

(Get Free Report)

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.

Featured Stories

Receive News & Ratings for Radiopharm Theranostics Limited - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radiopharm Theranostics Limited - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.